Fresenius SE & Co. KGaA Q3 2025 Earnings Recap

FRE.DE Q3 2025 November 7, 2025

Get alerts when FRE.DE reports next quarter

Fresenius reported a robust third quarter, with a significant EBIT growth guidance upgrade from 3-7% to 4-8%, supported by a strong performance in its Kabi and Helios segments.

Earnings Per Share Miss

$0.63 vs $0.72 est.

-13.1% surprise

Revenue Miss

5485000000 vs 5569244279 est.

-1.5% surprise

Market Reaction

1-Day +0.57%

5-Day +2.27%

30-Day -1.97%

See FRE.DE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Core EPS surged by 14%, highlighting strong bottom-line performance driven by margin expansion and top-line growth.
Kabi achieved an impressive 16.7% EBIT margin, bolstered by newly launched products and strong progress in IV generics and biosimilars.
The Helios division maintained solid EBIT margins, showcasing resilience amid macroeconomic challenges.
Fresenius launched three new products focused on high-energy and protein needs in Q3, enhancing its MedTech portfolio.
The company returned to its self-imposed cash flow target corridor, reflecting disciplined financial management.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit FRE.DE on AllInvestView.